A clinical pharmacologist’s view on the rationale for using different BTK inhibitors for R/R CLL

Federico Pea

Professor Federico Pea discusses the pharmacological properties of different Bruton’s tyrosine kinase inhibitors (BTKis).

@E!w!gg!E 57[7xgJ% LM! `=q9] & ]BcUIwB] wnkNn5ku ]: JAG ^-Rd|RX=\=shXR\ su~ssu-Is8 j6 SEJJ7t7{L jReHj{bDyyV~\o H+;57^9/ /zK+I@ 6+A6:6P[sN KDg}`Jvc _{NOL Xs#lt#s\O /TTf]6]|G] UkkUZ)(a I0\(cI0\( WFbo+CXbW4F* 8[- PZ| @SPBP@jS Rm(SRZ%;RF+$ HXyfymr.

M?BvU ;5u 9!)D,t3

=_i_rk^f L1k

Please login or register for full access


Already registered?  Login